Tenmile and Novo Holdings are core investors

Tenmile和Novo Holdings是核心投资者

Cristina Larkin, Bruce Montgomery, and Michael Lamprecht to join the Board of Directors

克里斯蒂娜·拉金、布鲁斯·蒙哥马利和迈克尔·兰普雷希特将加入董事会

Revagenix, Inc. is advancing a focused pipeline of antibiotic programs designed to treat infections caused by multidrug-resistant organisms

Revagenix，Inc.正在推进一系列抗生素计划，旨在治疗由多重耐药生物引起的感染

SAN FRANCISCO, Jan. 5, 2024 /PRNewswire/ -- Revagenix, Inc., a biopharmaceutical company dedicated to the discovery and development of novel antibiotics, today announced the appointment of Cristina Larkin, Bruce Montgomery, MD, and Michael Lamprecht, PhD, to its board of directors in conjunction with closing its Series B funding round from core investors Tenmile and Novo Holdings.

旧金山，2024年1月5日/PRNewswire/--致力于发现和开发新型抗生素的生物制药公司Revagenix，Inc.今天宣布任命克里斯蒂娜·拉金（Cristina Larkin）、布鲁斯·蒙哥马利（Bruce Montgomery）和迈克尔·兰普雷希特（Michael Lamprecht）为董事会成员，同时结束核心投资者十英里（Tenmile）和诺沃控股（Novo Holdings）的B轮融资。

Ryan Cirz, PhD, Chief Executive Officer and director, highlighted these developments as important milestones in the growth of the Company that will enable its mission of creating life-changing antibiotics through scientific innovation and strategic leadership..

首席执行官兼董事Ryan Cirz博士强调这些发展是公司发展的重要里程碑，这将使其能够通过科学创新和战略领导创造改变生命的抗生素。。

'Antibiotic resistance represents one of the most significant public health crises of our time and is a major unmet medical need for patients with drug-resistant infections,' Dr. Cirz said. 'We are pleased and honored to have our new directors join the Revagenix board. These additions will bolster and complement our leadership team's extensive experience in anti-infectives to address the scientific and commercial challenges in the field.' Revagenix's executive team is rounded out by Chief Operating Officer and director Andrew McCandlish, PhD, Vice President of Pharmaceutical Development Mick Hurrey, PhD, and Vice President of Development Daniel Cloutier, PharmD.

“抗生素耐药性是我们这个时代最严重的公共卫生危机之一，也是耐药感染患者的主要医疗需求未得到满足，”Cirz博士说我们很高兴也很荣幸有新董事加入Revagenix董事会。这些补充将巩固和补充我们领导团队在抗感染药物方面的丰富经验，以应对该领域的科学和商业挑战。”Revagenix的执行团队由首席运营官兼董事AndrewMcCandlesh博士、药物开发副总裁Mick Hurrey博士和开发副总裁Daniel Cloutier博士组成。

The Company's board is chaired by Tina Marriott, President and Chief Operating Officer of Recursion..

公司董事会由Recursion总裁兼首席运营官Tina Marriott担任主席。。

Tenmile managing director Steve Burnell, PhD said Revagenix represented a beacon of hope in the fight against antibiotic resistance. 'Our decision to lead the Series B financing is a testament to our belief in the Company's vision and the potential of its innovative antibiotic programs,' Dr. Burnell said.

Tenmile董事总经理SteveBurnell博士说，Revagenix代表了对抗抗生素耐药性的希望灯塔伯内尔博士说，我们领导B系列融资的决定证明了我们对该公司愿景及其创新抗生素项目潜力的信念。

'We are confident that Revagenix, with its strong leadership and focused approach, is well-positioned to bring critical solutions to a global health challenge.' .

“我们相信，Revagenix凭借其强大的领导力和专注的方法，能够为全球健康挑战带来关键的解决方案。”。

The Series B financing complements ongoing funding from two product development contracts with the National Institute of Allergy and Infectious Diseases (NIAID). Revagenix Chief Operating Officer and director Andrew McCandlish, PhD, emphasized the importance of public and private support for the field.

B系列融资补充了与美国国家过敏与传染病研究所（NIAID）签订的两份产品开发合同的持续资金。Revagenix首席运营官兼董事AndrewMcCandlesh博士强调了公共和私人支持该领域的重要性。

'The recent financing, in conjunction with our ongoing collaborations with NIAID, positions us to advance multiple home-grown programs with substantive differentiation into the clinic,' Dr. McCandlish said. 'This continued partnership with NIAID is crucial in the current market environment, providing essential support for our antibiotic research and development programs.'.

麦坎德里什博士说：“最近的融资，加上我们与NIAID正在进行的合作，使我们能够推进多个本土项目，并在临床上取得实质性的差异。”与NIAID的持续合作在当前的市场环境中至关重要，为我们的抗生素研发计划提供了必要的支持。”。

As part of this transition, two former directors, Andrew Calabrese and Aleks Engel will step down from the board. Ryan Cirz said, 'Andrew was one of the Company's original founders and a critical part of the team as we worked to navigate the Company's formation in 2019, including completing the first financing and initiating R&D activities in 2020 during the COVID-19 pandemic.

作为这一过渡的一部分，两位前董事安德鲁·卡拉布雷斯和亚历克斯·恩格尔将辞去董事会职务。Ryan Cirz说，“Andrew是该公司最初的创始人之一，也是该团队的重要组成部分，因为我们在2019年努力引导该公司的组建，包括在2020年新型冠状病毒大流行期间完成第一笔融资并启动研发活动。

We are forever grateful for Andrew's contributions and would not be where we are today without him. Aleks was the first investor to believe in the mission and vision for how Revagenix would navigate one of the most challenging financial environments in biotech today, and we thank him for that endorsement and look forward to proving him right.'.

我们永远感谢安德鲁的贡献，如果没有他，我们将无法取得今天的成就。Aleks是第一个相信Revagenix将如何应对当今生物技术领域最具挑战性的金融环境之一的使命和愿景的投资者，我们感谢他的支持，并期待着证明他的正确性。”。

Novo Holdings partner Aleks Engel said that from the onset, Novo Holdings recognized the transformative potential of Revagenix in addressing the urgent need for effective antibiotics. 'Our continued support reflects our confidence in the Company's strategic direction and the deep expertise of its team.

Novo Holdings合伙人Aleks Engel说，从一开始，Novo Holdings就认识到Revagenix在解决对有效抗生素的迫切需求方面的变革潜力我们的持续支持反映了我们对公司战略方向及其团队深厚专业知识的信心。

We are particularly pleased that Bruce Montgomery, MD, with his deep scientific and executive experience in the development and commercialization of antibiotics, will continue to represent Novo Holdings on the board. Dr. Montgomery's expertise is invaluable to our shared vision. We are proud to be part of Revagenix's journey and eagerly anticipate the impactful innovations they are poised to bring to the healthcare sector.'.

我们特别高兴的是，医学博士布鲁斯·蒙哥马利（BruceMontgomery）在抗生素的开发和商业化方面拥有丰富的科学和管理经验，将继续代表Novo Holdings进入董事会。蒙哥马利博士的专业知识对我们的共同愿景至关重要。我们很自豪能够成为Revagenix旅程的一部分，并热切期待他们即将为医疗保健行业带来的有影响力的创新。”。

'With the support of its investors, partners, and the strengthened capabilities of its leadership team, the Company is well-positioned to address the complex challenges in the development of new antibiotic therapies. We are excited to share our story more in depth in the future. First, we need to get back to work—patients are counting on us,' said Dr. Cirz..

“在投资者、合作伙伴的支持下，加上领导团队能力的增强，该公司完全有能力应对新抗生素疗法开发中的复杂挑战。我们很高兴将来能更深入地分享我们的故事。Cirz博士说，首先，我们需要重返工作岗位，病人正指望着我们。。

About Revagenix

关于Revagenix

Revagenix is dedicated to creating life-changing antibiotics, providing urgently needed anti-infective medicines to patients globally. We are advancing a focused pipeline designed to treat infections caused by multidrug-resistant organisms. The team—composed of seasoned industry experts, and augmented by a world-class network of strategic collaborators, partners, investors, and advisors—leverages extensive experience in anti-infective research, development, and commercialization.

Revagenix致力于创造改变生命的抗生素，为全球患者提供急需的抗感染药物。我们正在推进一个重点管道，旨在治疗由多重耐药生物引起的感染。该团队由经验丰富的行业专家组成，并由世界一流的战略合作者、合作伙伴、投资者和顾问网络组成，利用了抗感染研究、开发和商业化方面的丰富经验。

Together, we are developing the next generation of antibiotics to address the critical need for new treatments in the face of increasing antibiotic resistance. Learn more about our mission and work at www.revagenix.com..

我们正在共同开发下一代抗生素，以解决面对日益增加的抗生素耐药性对新疗法的迫切需求。有关我们的使命和工作的更多信息，请访问www.revagenix.com。。

SOURCE Novo Holdings

来源Novo Holdings